Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BNGO Stock Forecast 2026-2027
$1.17
Current Price
$13.66M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to BNGO Price Targets
+412.8%
To High Target of $6.00
+327.4%
To Median Target of $5.00
+241.9%
To Low Target of $4.00
BNGO Price Momentum
-2.5%
1 Week Change
+0.9%
1 Month Change
-65.6%
1 Year Change
-23.5%
Year-to-Date Change
-78.7%
From 52W High of $5.50
+10.4%
From 52W Low of $1.06
📊 TOP ANALYST CALLS
Did BNGO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if BioNano is one of their latest high-conviction picks.
Latest BNGO Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, BNGO has a bullish consensus with a median price target of $5.00 (ranging from $4.00 to $6.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $1.17, the median forecast implies a 327.4% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yi Chen at HC Wainwright & Co., projecting a 412.8% upside. Conversely, the most conservative target is provided by Sung Ji Nam at Scotiabank, suggesting a 241.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BNGO Analyst Ratings
2
Buy
0
Hold
0
Sell
BNGO Price Target Range
Low
$4.00
Average
$5.00
High
$6.00
Current: $1.17
Latest BNGO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BNGO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 13, 2026 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $6.00 |
| Nov 24, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 18, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 20, 2025 | Maxim Group | Buy | Upgrade | $N/A | |
| Apr 9, 2025 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Apr 2, 2025 | Scotiabank | Sector Perform | Maintains | $N/A | |
| Nov 15, 2024 | Ladenburg Thalmann | Neutral | Downgrade | $N/A | |
| Sep 10, 2024 | BTIG | Mark Massaro | Neutral | Downgrade | $N/A |
| Aug 28, 2024 | Scotiabank | Sung Ji Nam | Sector Perform | Downgrade | $1.00 |
| May 16, 2024 | BTIG | Buy | Maintains | $N/A | |
| Mar 7, 2024 | Scotiabank | Sector Outperform | Maintains | $N/A | |
| Nov 13, 2023 | Maxim Group | Hold | Downgrade | $N/A | |
| Aug 10, 2023 | BTIG | Buy | Maintains | $N/A | |
| Jun 9, 2023 | BTIG | Buy | Maintains | $N/A | |
| May 25, 2023 | EF Hutton | Buy | Initiates | $1.75 | |
| May 18, 2023 | BTIG | Mark Massaro | Buy | Maintains | $2.00 |
| Apr 24, 2023 | BTIG | Buy | Maintains | $N/A | |
| Mar 10, 2023 | BTIG | Buy | Maintains | $N/A | |
| Feb 6, 2023 | Oppenheimer | Francois Brisebois | Outperform | Maintains | $9.00 |
| Feb 5, 2023 | BTIG | Buy | Maintains | $N/A |
Bionano Genomics Inc. (BNGO) Competitors
The following stocks are similar to BioNano based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Bionano Genomics Inc. (BNGO) Financial Data
Bionano Genomics Inc. has a market capitalization of $13.66M with a P/E ratio of 0.0x. The company generates $28.74M in trailing twelve-month revenue with a -109.9% profit margin.
Revenue growth is +3.6% quarter-over-quarter, while maintaining an operating margin of -118.1% and return on equity of -73.8%.
Valuation Metrics
Market Cap
$13.66M
Enterprise Value
$16.03M
P/E Ratio
0.0x
PEG Ratio
0.0x
Price/Sales
0.5x
Growth & Margins
Revenue Growth (YoY)
+3.6%
Gross Margin
+48.6%
Operating Margin
-118.1%
Net Margin
-109.9%
EPS Growth
+3.6%
Financial Health
Cash/Price Ratio
+107.3%
Current Ratio
1.8x
Debt/Equity
45.4x
ROE
-73.8%
ROA
-28.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Bionano Genomics Inc. (BNGO) Business Model
About Bionano Genomics Inc.
What They Do
Develops genome analysis software for labs.
Business Model
The company generates revenue by offering software solutions that help genomics laboratories analyze and interpret genomic data. Its products are utilized in both research and clinical settings, addressing the need for comprehensive insights in cancer diagnosis and genetic disease detection.
Additional Information
Bionano Genomics operates in the life sciences and healthcare technology sector, focusing on enhancing precision medicine and diagnostic capabilities. It serves a global market, catering to both clinical laboratories and research institutions.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
344
CEO
Dr. Robert Erik Holmlin M.B.A., Ph.D.
Country
United States
IPO Year
N/A
Website
www.bionano.comBionano Genomics Inc. (BNGO) Latest News & Analysis
Latest News
Quick Summary
Bionano Genomics appointed Dr. Alex Hastie as Chief Scientific Officer, effective July 20, 2026, to lead global scientific strategy and research initiatives.
Why It Matters
The appointment of a new CSO can signal a shift in strategic direction and innovation potential, impacting Bionano Genomics' growth prospects and competitive positioning in the genome analysis market.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Bionano Genomics (Nasdaq: BNGO) reported a 67% increase in studies featuring optical genome mapping at the 2026 ESHG conference, with 35 studies presented, indicating growing global adoption.
Why It Matters
The significant increase in studies featuring optical genome mapping (OGM) indicates growing demand and adoption, potentially boosting Bionano Genomics' market position and future revenue prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Bionano Genomics (Nasdaq: BNGO) reported 13 studies in 2026, analyzing 730 samples, highlighting the effectiveness of optical genome mapping in detecting structural variants related to reproductive health issues.
Why It Matters
The announcement highlights Bionano Genomics' advancements in optical genome mapping, potentially enhancing its market position and driving demand in reproductive health, affecting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Bionano Genomics (BNGO) has been upgraded to a Zacks Rank #2 (Buy) due to increasing optimism about its earnings prospects, suggesting potential for stock price growth.
Why It Matters
Bionano Genomics' upgrade to a Zacks Rank #2 signals strong earnings potential, likely boosting investor confidence and driving stock price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Bionano Genomics published a study showing its optical genome mapping detected 97.8% of genomic abnormalities in T-cell acute lymphoblastic leukemia, significantly higher than the 55% rate of conventional methods.
Why It Matters
Bionano Genomics' OGM technology significantly outperforms conventional methods in detecting T-ALL abnormalities, highlighting its potential to revolutionize cancer diagnostics and treatment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Bionano Genomics (Nasdaq: BNGO) has retired all $20M of its Senior Secured Convertible Debentures using cash on hand, enhancing its financial position.
Why It Matters
Bionano Genomics' retirement of $20M in convertible debentures reduces debt, improves financial stability, and may enhance share value, signaling stronger future prospects to investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About BNGO Stock
What is Bionano Genomics Inc.'s (BNGO) stock forecast for 2027?
Based on our analysis of 5 Wall Street analysts, Bionano Genomics Inc. (BNGO) has a median price target of $5.00. The highest price target is $6.00 and the lowest is $4.00.
Is BNGO stock a good investment in 2027?
According to current analyst ratings, BNGO has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.17. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BNGO stock?
Wall Street analysts predict BNGO stock could reach $5.00 in the next 12 months. This represents a 327.4% increase from the current price of $1.17. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Bionano Genomics Inc.'s business model?
The company generates revenue by offering software solutions that help genomics laboratories analyze and interpret genomic data. Its products are utilized in both research and clinical settings, addressing the need for comprehensive insights in cancer diagnosis and genetic disease detection.
What is the highest forecasted price for BNGO Bionano Genomics Inc.?
The highest price target for BNGO is $6.00 from Yi Chen at HC Wainwright & Co., which represents a 412.8% increase from the current price of $1.17.
What is the lowest forecasted price for BNGO Bionano Genomics Inc.?
The lowest price target for BNGO is $4.00 from Sung Ji Nam at Scotiabank, which represents a 241.9% increase from the current price of $1.17.
What is the overall BNGO consensus from analysts for Bionano Genomics Inc.?
The overall analyst consensus for BNGO is bullish. Out of 5 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are BNGO stock price projections?
Stock price projections, including those for Bionano Genomics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:11 AM UTC